NAD+ vs Epitalon vs 5-Amino-1MQ: The Longevity Compounds Compared

"Longevity compound" is doing a lot of work as a category, because the three most common ones address aging at three different levels. NAD+ tops up the coenzyme that runs cellular energy and repair. Epitalon acts on telomeres and the body's circadian clock. 5-Amino-1MQ blocks an enzyme that quietly drains NAD+ while nudging metabolism at the same time.

They get lumped together because they all sit under the longevity banner, but choosing between them - or, more usefully, deciding how they fit together - means understanding that they're pulling different levers on the aging process. One is about running the machinery, one is about protecting the blueprint, one is about removing a metabolic brake.

Here's what each actually does, how strong the evidence really is, and where each earns its place.

Why NAD+ sits at the centre of the aging story

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, and it is genuinely central to how cells age. It does two jobs. It shuttles electrons in the reactions that produce cellular energy, and it acts as the fuel for two families of repair and regulation enzymes: the sirtuins, which govern DNA repair, inflammation and metabolic health, and the PARPs, which repair damaged DNA.

The problem is that NAD+ declines steadily with age - by some estimates roughly halving between young adulthood and middle age. As it falls, sirtuin and PARP activity falls with it, mitochondrial function degrades, and the cell's capacity to repair itself weakens. A large part of the longevity field is, in one way or another, an attempt to keep NAD+ from collapsing.

That framing is what connects all three compounds here. NAD+ therapy raises the coenzyme directly. 5-Amino-1MQ raises it indirectly by blocking a pathway that consumes it. Epitalon works on a different axis entirely - telomeres and circadian regulation - but is grouped in because it targets the same ultimate goal of slowing biological aging. Understanding the NAD+ decline is the key that makes the comparison legible.

NAD+: refilling the tank directly

The most direct approach is to raise NAD+ itself, either with NAD+ administered as an injection or IV, or with precursors like NMN and NR that the body converts into NAD+. The goal is the same: restore the coenzyme to more youthful levels so sirtuins, PARPs and mitochondria have the substrate they need.

What the evidence supports is clear and also modest. Human trials of NMN and NR consistently show they do raise blood NAD+ levels - the biochemistry works. What's less settled is how much that translates into measurable clinical outcomes; the human data on energy, metabolic markers and performance is promising but not dramatic, and the sweeping lifespan claims outrun the trials. Direct NAD+ injection produces a more pronounced acute effect than oral precursors, which is why people chasing a noticeable energy shift often prefer it despite the inconvenience.

In practice, NAD+ is used for cellular energy, mitochondrial support and general vitality, dosed as subcutaneous injections or IV courses, with oral precursors as a gentler daily option. Where it wins is immediacy and mechanism: it addresses the decline head-on, and the effect on subjective energy is the most commonly reported of the three. Where it falls short is proof of long-term outcomes - it's the best-understood mechanism with the least dramatic proven payoff.

Epitalon: telomeres and the body clock

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide - four amino acids - modelled on epithalamin, a substance from the pineal gland. It works on a completely different axis from the NAD+ story, which is why it's the most distinctive of the three.

Its headline mechanism is telomerase activation. Telomeres are the protective caps on chromosomes that shorten each time a cell divides; when they get too short, the cell stops dividing. Epitalon has been shown in cell studies to activate telomerase, the enzyme that can lengthen telomeres, at least in culture. Its second role is regulating the pineal gland and melatonin, which means it influences circadian rhythm and sleep - an under-appreciated lever on aging, since circadian disruption itself accelerates it.

The honest caveat is that much of the supporting research comes from a specific body of Russian work spanning decades, with limited large-scale independent replication. The telomerase and circadian mechanisms are real and interesting; the long human outcome data is thinner than the enthusiasm around it.

Epitalon is typically used in short cycles - often a course of daily injections a couple of times a year - rather than continuously, reflecting its role as a periodic reset rather than a daily support. Where it wins is that it targets a dimension of aging the NAD+ compounds don't touch at all: the blueprint and the clock. For someone whose interest is telomere maintenance and circadian health, it's the only one of the three that's even in that conversation.

5-Amino-1MQ: releasing a metabolic brake

5-Amino-1MQ is a small molecule that inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that methylates nicotinamide. That matters for two reasons at once, which is what makes this compound a bridge between the longevity and metabolic categories.

First, by inhibiting NNMT, 5-Amino-1MQ preserves the nicotinamide pool that feeds NAD+ production - so it raises NAD+ indirectly, by stopping it being drained, rather than by adding it. Second, NNMT is overexpressed in fat tissue and acts as a metabolic brake; blocking it shifts cellular metabolism away from fat storage, activates the sirtuins SIRT1 and SIRT3, and helps preserve lean tissue. The result is a compound that supports NAD+-dependent longevity pathways and does something visible to body composition in the same move.

The evidence is earlier-stage than for NAD+ precursors - largely preclinical, with a clean mechanistic story and encouraging tolerability. It's typically dosed as a small daily oral or subcutaneous amount without strict cycling.

Where it wins is the two-for-one: it defends NAD+ through a different route than direct supplementation, and it carries a metabolic and body-composition benefit the other two don't. For someone whose longevity interest overlaps with staying lean, it's the most practically appealing of the three.

Head to head

• Mechanism - NAD+: refills the coenzyme directly. Epitalon: activates telomerase and regulates the pineal/circadian axis. 5-Amino-1MQ: inhibits NNMT to preserve NAD+ and lift a metabolic brake.
• Aging lever - NAD+ runs the machinery (energy, sirtuins, mitochondria); Epitalon protects the blueprint and the clock (telomeres, circadian); 5-Amino-1MQ removes a drain and shifts metabolism.
• Evidence - NAD+ precursors have the most human data (they reliably raise NAD+, with modest clinical outcomes); Epitalon leans on a specific Russian literature with limited replication; 5-Amino-1MQ is promising but mostly preclinical.
• Most-reported effect - NAD+: subjective energy. Epitalon: sleep/circadian and a sense of periodic reset. 5-Amino-1MQ: body composition and metabolic tone.
• Use pattern - NAD+ ongoing (injections, IV, or daily precursors); Epitalon in short periodic cycles; 5-Amino-1MQ low daily dose.
• Overlap - NAD+ and 5-Amino-1MQ both raise NAD+ by opposite routes and pair naturally; Epitalon sits on its own axis and complements rather than duplicates either.

Who should choose what — and why they stack

NAD+ makes sense if your priority is cellular energy and mitochondrial support now, and you want the mechanism with the most direct evidence. It's the one most people feel, and the most straightforward to reason about.

Epitalon makes sense if your interest is the dimension the others ignore - telomere maintenance and circadian health - and you're comfortable with periodic cycles and a thinner outcome literature. It's the long-horizon, blueprint-level choice.

5-Amino-1MQ makes sense if you want NAD+ support with a metabolic and body-composition payoff, and you like that it works by removing a brake rather than adding a substrate.

The more useful framing is that these aren't really rivals. They hit different nodes of the same aging network, which is why they combine cleanly: NAD+ or its precursors to top up the coenzyme, 5-Amino-1MQ to stop it draining and shift metabolism, Epitalon cycled in for the telomere and circadian axis. A thoughtful longevity stack tends to include more than one precisely because each covers what the others miss.

The honest conclusion

If you only run one and want the clearest mechanism and the most-felt effect, start with NAD+ (or an NMN/NR precursor). If you want a metabolic benefit alongside the longevity angle, 5-Amino-1MQ is the more interesting single pick. Epitalon is the specialist - worth it if telomeres and circadian health are specifically what you're after, less so as a general first move given the evidence base.

The sober caveat across all three: the mechanisms are real, but the leap from "raises NAD+ in a trial" or "activates telomerase in a dish" to "extends healthy human lifespan" is exactly the leap the data hasn't made yet. These are reasonable, mechanistically-grounded bets on healthspan, deployed best alongside the unglamorous fundamentals - sleep, training, and metabolic health - that still do more for aging than any peptide.